Gap finder

Search review questions

Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.

Population

Intervention or exposure

Comparison

Outcome

Any field or review title

Field or topic

Source

Review versions

1,886 questions in 74 reviews · Skin

current versions

No studies 542 · 28.7%Ungraded 130 · 6.9%Very low 326 · 17.3%Low 434 · 23%Moderate 348 · 18.5%High 106 · 5.6%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Question	Effect	Evidence	Status / GRADE
Tacrolimus 0.03% vs pimecrolimus 1% Physician's assessment of global response of improvement · people with atopic dermatitis Topical tacrolimus for atopic dermatitis (2015) · Cochrane	RR 1.42 [1.02, 1.98]	1 study · 139 participants	Low
Tacrolimus 0.03% vs pimecrolimus 1% Adverse effects ‐ application site reaction · people with atopic dermatitis Topical tacrolimus for atopic dermatitis (2015) · Cochrane	RR 1.07 [0.6, 1.91]	1 study · 141 participants	Low
Tacrolimus 0.1% vs corticosteroids Physician's assessment of global response of improvement, clear or excellent ‐ tacrolimus 0.1% versus hydrocortisone butyrate: 3 weeks · people with atopic dermatitis Topical tacrolimus for atopic dermatitis (2015) · Cochrane	RR 0.95 [0.78, 1.16]	1 study · 377 participants	Low
Tacrolimus 0.03% vs pimecrolimus 1% Adverse effects ‐ burning · people with atopic dermatitis Topical tacrolimus for atopic dermatitis (2015) · Cochrane	RR 0.87 [0.43, 1.75]	1 study · 141 participants	Low
Tacrolimus 0.03% vs pimecrolimus 1% Adverse effects ‐ itching · people with atopic dermatitis Topical tacrolimus for atopic dermatitis (2015) · Cochrane	RR 2.37 [0.96, 5.81]	1 study · 141 participants	Low
Tacrolimus 0.03% vs pimecrolimus 1% Adverse effects ‐ erythema · people with atopic dermatitis Topical tacrolimus for atopic dermatitis (2015) · Cochrane	RR 2.2 [0.89, 5.46]	1 study · 141 participants	Low
Tacrolimus 0.1% vs ciclosporin Adverse effects · people with atopic dermatitis Topical tacrolimus for atopic dermatitis (2015) · Cochrane	RR 1 [0.31, 3.28]	1 study · 30 participants	Very low
Tacrolimus 0.1% vs corticosteroids Physician's assessment of global response of improvement, clear or excellent ‐ tacrolimus 0.1% versus hydrocortisone acetate and butyrate 0.1%: short term (6 months) · people with atopic dermatitis Topical tacrolimus for atopic dermatitis (2015) · Cochrane	RR 1.32 [1.17, 1.49]	1 study · 972 participants	Moderate
Tacrolimus 0.1% vs corticosteroids Adverse effects: burning ‐ tacrolimus 0.1% versus hydrocortisone acetate 0.1%: 3 weeks · people with atopic dermatitis Topical tacrolimus for atopic dermatitis (2015) · Cochrane	RR 2.91 [1.6, 5.28]	1 study · 371 participants	Moderate
Tacrolimus 0.1% vs corticosteroids Adverse effects: burning ‐ tacrolimus 0.1% versus hydrocortisone butyrate: 3 weeks · people with atopic dermatitis Topical tacrolimus for atopic dermatitis (2015) · Cochrane	RR 4.59 [3.1, 6.78]	1 study · 377 participants	Moderate
Tacrolimus 0.1% vs corticosteroids Adverse effects: burning ‐ tacrolimus 0.1% versus hydrocortisone acetate and butyrate 0.1%: 6 months · people with atopic dermatitis Topical tacrolimus for atopic dermatitis (2015) · Cochrane	RR 3.79 [2.99, 4.81]	1 study · 972 participants	Moderate
Tacrolimus 0.1% vs corticosteroids Participant's self‐assessment of global response of improvement · people with atopic dermatitis Topical tacrolimus for atopic dermatitis (2015) · Cochrane	RR 1.21 [1.13, 1.29]	1 study · 974 participants	Low
Tacrolimus 0.1% vs pimecrolimus 1% Physician's assessment of global response of improvement, clear or excellent ‐ 6 weeks · people with atopic dermatitis Topical tacrolimus for atopic dermatitis (2015) · Cochrane	RR 1.8 [1.34, 2.42]	2 studies · 506 participants	Moderate
Tacrolimus 0.1% vs pimecrolimus 1% Adverse effects ‐ 6 weeks · people with atopic dermatitis Topical tacrolimus for atopic dermatitis (2015) · Cochrane	RR 0.89 [0.47, 1.71]	2 studies · 506 participants	Very low
Etanercept vs placebo PASI 75 Participants achieving a 75% improvement in the Psoriasis Area and Severity Index · people with paediatric psoriasis Anti‐TNF agents for paediatric psoriasis (2015) · Cochrane	RR 4.95 [2.83, 8.65]	1 study · 211 participants	High
Etanercept vs placebo PASI 50 Participants achieving a 50% improvement in the Psoriasis Area and Severity Index · people with paediatric psoriasis Anti‐TNF agents for paediatric psoriasis (2015) · Cochrane	RR 3.26 [2.26, 4.71]	1 study · 211 participants	High
Etanercept vs placebo PASI 90 Participants achieving a 90% improvement in the Psoriasis Area and Severity Index · people with paediatric psoriasis Anti‐TNF agents for paediatric psoriasis (2015) · Cochrane	RR 4.1 [1.88, 8.95]	1 study · 211 participants	High
Etanercept vs placebo PGA Participants achieving a PGA of 'clear' or 'almost clear' · people with paediatric psoriasis Anti‐TNF agents for paediatric psoriasis (2015) · Cochrane	RR 3.96 [2.36, 6.66]	1 study · 211 participants	High
Etanercept vs placebo CDLQI Scores range from 0 to 30. Lower scores indicate better health‐related quality of life. Calculations are based on the change from baseline to week 12 in both groups · people with paediatric psoriasis Anti‐TNF agents for paediatric psoriasis (2015) · Cochrane	no estimate extracted	1 study · 211 participants	Moderate
Adalimumab weekly vs placebo Change in DLQI score (imputation) · participants with hidradenitis suppurativa Interventions for hidradenitis suppurativa (2015) · Cochrane	no estimate extracted	1 study · 102 participants	Moderate
Adalimumab every other week vs placebo Frequency of treatment discontinuation · participants with hidradenitis suppurativa Interventions for hidradenitis suppurativa (2015) · Cochrane	RR 4.91 [0.24, 99.74]	2 studies · 124 participants	High
Adalimumab every other week vs placebo Proportion of participants with infectious adverse effects · participants with hidradenitis suppurativa Interventions for hidradenitis suppurativa (2015) · Cochrane	RR 1.6 [0.57, 4.53]	2 studies · 124 participants	High
Adalimumab every other week vs placebo Change in Pain VAS · participants with hidradenitis suppurativa Interventions for hidradenitis suppurativa (2015) · Cochrane	no estimate extracted	1 study · 21 participants	Low
Adalimumab every other week vs placebo Proportion with improvement in pain · participants with hidradenitis suppurativa Interventions for hidradenitis suppurativa (2015) · Cochrane	RR 1.34 [0.73, 2.43]	1 study · 95 participants	Moderate
Adalimumab every other week vs placebo Change in Sartorius scale score (LOCF) · participants with hidradenitis suppurativa Interventions for hidradenitis suppurativa (2015) · Cochrane	no estimate extracted	2 studies · 124 participants	Moderate
Infliximab vs placebo At least 50% decrease in HS Severity Index · participants with hidradenitis suppurativa Interventions for hidradenitis suppurativa (2015) · Cochrane	RR 4.8 [0.6, 38.48]	1 study · 33 participants	Moderate
Infliximab vs placebo Physician global assessment · participants with hidradenitis suppurativa Interventions for hidradenitis suppurativa (2015) · Cochrane	RR 4.8 [1.66, 13.9]	1 study · 33 participants	Moderate
Etanercept vs placebo Dermatology Life Quality Index · participants with hidradenitis suppurativa Interventions for hidradenitis suppurativa (2015) · Cochrane	no estimate extracted	1 study · 17 participants	Moderate
Topical clindamycin vs placebo Adverse effects (non‐serious) · participants with hidradenitis suppurativa Interventions for hidradenitis suppurativa (2015) · Cochrane	RR 0.72 [0.14, 3.64]	1 study · 27 participants	Moderate
Oral tetracycline vs topical clindamycin Participant global assessment VAS Visual analogue scale (VAS) (0 to 100 mm) · participants with hidradenitis suppurativa Interventions for hidradenitis suppurativa (2015) · Cochrane	no estimate extracted	1 study · 34 participants	Low
Adalimumab weekly vs placebo Change in DLQI score (LOCF) · participants with hidradenitis suppurativa Interventions for hidradenitis suppurativa (2015) · Cochrane	no estimate extracted	1 study · 102 participants	Moderate
Oral tetracycline vs topical clindamycin Pain VAS VAS (0 to 100 mm) · participants with hidradenitis suppurativa Interventions for hidradenitis suppurativa (2015) · Cochrane	no estimate extracted	1 study · 34 participants	Low
Oral tetracycline vs topical clindamycin Nodules score Nodule count · participants with hidradenitis suppurativa Interventions for hidradenitis suppurativa (2015) · Cochrane	no estimate extracted	1 study · 34 participants	Low
Oral tetracycline vs topical clindamycin Abscesses score Abscess count · participants with hidradenitis suppurativa Interventions for hidradenitis suppurativa (2015) · Cochrane	no estimate extracted	1 study · 34 participants	Low
Oral tetracycline vs topical clindamycin Physician global assessment VAS VAS (0 to 100 mm) · participants with hidradenitis suppurativa Interventions for hidradenitis suppurativa (2015) · Cochrane	no estimate extracted	1 study · 34 participants	Low
Ethinyloestradiol and cyproterone acetate vs ethinyloestradiol and norgestrel Number of participants reporting non‐serious adverse effects · participants with hidradenitis suppurativa Interventions for hidradenitis suppurativa (2015) · Cochrane	RR 0.53 [0.29, 0.98]	1 study · 18 participants	Moderate
Ethinyloestradiol and cyproterone acetate vs ethinyloestradiol and norgestrel Participant global assessment VAS Scale from: 0 to 100 · participants with hidradenitis suppurativa Interventions for hidradenitis suppurativa (2015) · Cochrane	no estimate extracted	1 study · 17 participants	Moderate
Gentamicin sponge vs primary closure alone Adverse effects ‐ complication rate at 1 week after surgery · participants with hidradenitis suppurativa Interventions for hidradenitis suppurativa (2015) · Cochrane	RR 0.78 [0.58, 1.05]	1 study · 200 participants	Moderate
Gentamicin sponge vs primary closure alone Adverse effects ‐ complication rate at 3 months after surgery · participants with hidradenitis suppurativa Interventions for hidradenitis suppurativa (2015) · Cochrane	RR 0.9 [0.5, 1.62]	1 study · 200 participants	Moderate
Gentamicin sponge vs primary closure alone Recurrence rate at 3 months after surgery · participants with hidradenitis suppurativa Interventions for hidradenitis suppurativa (2015) · Cochrane	RR 0.96 [0.68, 1.34]	1 study · 200 participants	Moderate
Intense pulsed light vs no treatment Participant global assessment: satisfaction with treatment Questionnaire · participants with hidradenitis suppurativa Interventions for hidradenitis suppurativa (2015) · Cochrane	RR 9.67 [2.01, 46.43]	1 study · 34 participants	Low
Adalimumab weekly vs placebo Frequency of serious adverse effects · participants with hidradenitis suppurativa Interventions for hidradenitis suppurativa (2015) · Cochrane	RR 2 [0.38, 10.44]	1 study · 102 participants	Moderate
Intense pulsed light vs no treatment Participant global assessment: satisfaction with treatment ‐ axilla Questionnaire · participants with hidradenitis suppurativa Interventions for hidradenitis suppurativa (2015) · Cochrane	RR 21 [1.37, 322.28]	1 study · 24 participants	Low
Intense pulsed light vs no treatment Participant global assessment: satisfaction with treatment ‐ groin Questionnaire · participants with hidradenitis suppurativa Interventions for hidradenitis suppurativa (2015) · Cochrane	RR 5 [0.31, 79.94]	1 study · 8 participants	Low
Intense pulsed light vs no treatment Participant global assessment: satisfaction with treatment ‐ inframammary Questionnaire · participants with hidradenitis suppurativa Interventions for hidradenitis suppurativa (2015) · Cochrane	RR 3 [0.24, 37.67]	1 study · 2 participants	Low
Nd:YAG laser vs topical control Modified HS‐LASI score after 3 months · participants with hidradenitis suppurativa Interventions for hidradenitis suppurativa (2015) · Cochrane	no estimate extracted	1 study · 50 participants	Very low
Nd:YAG laser vs topical control Modified HS‐LASI score after 3 months ‐ axilla · participants with hidradenitis suppurativa Interventions for hidradenitis suppurativa (2015) · Cochrane	no estimate extracted	1 study · 20 participants	Very low
Nd:YAG laser vs topical control Modified HS‐LASI score after 3 months ‐ groin · participants with hidradenitis suppurativa Interventions for hidradenitis suppurativa (2015) · Cochrane	no estimate extracted	1 study · 22 participants	Very low
Nd:YAG laser vs topical control Modified HS‐LASI score after 3 months ‐ inframammary · participants with hidradenitis suppurativa Interventions for hidradenitis suppurativa (2015) · Cochrane	no estimate extracted	1 study · 8 participants	Very low
Nd:YAG laser vs topical control Percentage change in modified HS‐LASI score after 5 months compared with baseline · participants with hidradenitis suppurativa Interventions for hidradenitis suppurativa (2015) · Cochrane	no estimate extracted	1 study · 50 participants	Very low